Key result
Oral quinidine treatment in three pediatric patients with KCNT1-related developmental and epileptic encephalopathies resulted in a 50% to 90% reduction in seizure frequency.
Why the study?
Quinidine is gaining attention for treating epilepsy of infancy with migrating focal seizures due to KCNT1 variants, prompting evaluation of therapeutic drug monitoring in this setting.
Does oral quinidine reduce seizure frequency in pediatric patients with developmental and epileptic encephalopathies due to KCNT1 genetic variants?
Case Report (n=3)
Does oral quinidine reduce seizure frequency in pediatric patients with developmental and epileptic encephalopathies due to KCNT1 genetic variants?
Quinidine is a promising treatment for pediatric patients with DEE due to KCNT1 genetic variants, providing significant seizure reduction at sub-antiarrhythmic blood levels.
No takes yet. Share an insight, caveat, or question.
TDM may aid quinidine dosing in KCNT1 epilepsy; leaves open efficacy, safety, and optimal targets pending controlled trials.
Ferretti et al. (2022) conducted a case report in Developmental and epileptic encephalopathies (DEE) due to KCNT1 genetic variants (n=3). Quinidine was evaluated on Reduction in seizure frequency. Oral quinidine treatment in three pediatric patients with KCNT1-related developmental and epileptic encephalopathies resulted in a 50% to 90% reduction in seizure frequency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: